Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim Biotech's change in inventory for the quarter that ended in Mar. 2026 was €-19 Mil. It means Sartorius Stedim Biotech's inventory
increased by €19 Mil
from Dec. 2025 to Mar. 2026 .
Sartorius Stedim Biotech's change in inventory for the fiscal year that ended in Dec. 2025 was €-46 Mil. It means Sartorius Stedim Biotech's inventory
increased by €46 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sartorius Stedim Biotech's Days Inventory for the quarter that ended in Mar. 2026 was 154.12.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sartorius Stedim Biotech's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sartorius Stedim Biotech's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.92.
Sartorius Stedim Biotech (CHIX:DIMp) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sartorius Stedim Biotech's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sartorius Stedim Biotech's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech Change In Inventory Related Terms
Sartorius Stedim Biotech Change In Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech Change In Inventory Chart
Sartorius Stedim Biotech Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a Change In Inventory of €-54 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Change In Inventory too high?
Sartorius Stedim Biotech's current Change In Inventory is €-54 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Change In Inventory compare to ISRG and BDX?
Sartorius Stedim Biotech's Change In Inventory of €-54 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Devices & Instruments company?
A good Change In Inventory depends on the Medical Devices & Instruments industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Change In Inventory is €-54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €208.40, compared to a current price of €187.40 — trading 10.1% below its estimated fair value. The current Change In Inventory is €-54 Mil. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Change In Inventory is €-54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €187.40 is trading 10.1% below its estimated GF Value™ of €208.40.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
Change In Inventory: €-54 Mil
GF Value™: €208.40 vs. price of €187.40 (10.1% below fair value)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for CHIX:DIMP
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
